Business Context and Reporting Period
Company: Revelation Biosciences, Inc. (REVB)
Filing Type: Form 8-K (Current Report)
Date of Report: August 14, 2024
Reporting Period: Event-based report regarding Nasdaq listing compliance status as of the date of the Nasdaq notification letter.
Key Financial Metrics
The filing references specific financial data from the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, to justify the listing deficiency:
- Stockholders' Equity: $1,140,421
- Required Minimum Equity: $2,500,000 (Nasdaq Listing Rule 5550(b)(1))
- Alternative Compliance Standards Not Met:
- Market value of listed securities: Less than $35 million
- Net income from continuing operations: Less than $500,000 (for the most recent fiscal year or two of the last three)
Note: The filing does not provide specific values for revenue, cash flow, margins, or total debt.
Material Changes and Events
On August 14, 2024, the Company received a letter from The Nasdaq Stock Market LLC notifying it of non-compliance with the Stockholders' Equity Requirement. This deficiency is based on the reported stockholders' equity of $1,140,421, which falls significantly below the $2,500,000 threshold required for continued listing on The Nasdaq Capital Market.
Outlook, Management Commentary, and Risks
- Compliance Plan: The Company has 45 calendar days from the date of the Nasdaq Letter to submit a plan to regain compliance. Management intends to submit this plan within the allotted period.
- Extension Possibility: If the plan is accepted, Nasdaq may grant an extension of up to 180 calendar days to evidence compliance.
- Delisting Risk: If the plan is not accepted, or if the Company fails to regain compliance within the extension period, the Company may face delisting. The Company retains the right to a hearing before an independent panel, which would stay any suspension or delisting action pending the conclusion of the process.
- Current Trading Status: Neither the Nasdaq Letter nor the non-compliance has an immediate effect on the listing or trading of the Company's common stock (REVB) or warrants (REVBW).
- Uncertainty: Management states there can be no assurance that Nasdaq will grant an extension or that the Company will ultimately regain compliance.
Investor Verification Checklist
- Verify the specific details of the compliance plan the Company intends to submit within the 45-day window.
- Monitor subsequent filings for acceptance of the plan by Nasdaq staff and any granted extension periods.
- Review the full Form 10-Q for the quarter ended June 30, 2024, to analyze the causes of the equity deficiency and overall financial health.
- Track the market value of listed securities and net income figures to assess if alternative listing standards might be met in the future.